OGN Q2 2025

Q4 2025 Q3 2025 Q2 2025 Q1 2025

Earnings

Organon delivered a modest beat across both top and bottom lines in Q2 2025, though the results did little to quiet growing concerns about the women's health and generics company's longer-term trajectory. Non-GAAP EPS came in at $1.00, clearing the $… Read more Organon delivered a modest beat across both top and bottom lines in Q2 2025, though the results did little to quiet growing concerns about the women's health and generics company's longer-term trajectory. Non-GAAP EPS came in at $1.00, clearing the $0.94 consensus estimate by 6.36%, while revenue of $1.59 billion edged past the $1.56 billion consensus by 2.32%, even as sales slipped 0.8% year over year. The primary engine behind the earnings beat was disciplined cost control, with non-GAAP adjusted EBITDA margin expanding to 32.7% from 31.9% a year earlier as restructuring efforts trimmed operating expenses by 3%. Fertility products surged 15% on a constant-currency basis, helping Women's Health partially offset softness in Nexplanon and continued pressure in Established Brands from European patent losses. Organon also raised its full-year revenue guidance midpoint by $100 million to a range of $6.28 billion to $6.38 billion, aided by a significantly reduced foreign exchange headwind; still, a class-action lawsuit alleging securities fraud has added a fresh layer of investor unease around the stock.